This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

A Randomized Controlled Trial

Jean-Claude Tardif, MD; Jean Grégoire, MD; Philippe L. L’Allier, MD; Reda Ibrahim, MD; Jacques Lespérance, MD; Therese M. Heinonen, DVM; Simon Kouz, MD; Colin Berry, MD; Russell Basser, MD; Marc-André Lavoie, MD; Marie-Claude Guertin, PhD; Josep Rodés-Cabau, MD; for the Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators

JAMA. 2007;297:(doi:10.1001/jama.297.15.jpc70004).

Context  High-density lipoprotein (HDL) cholesterol is an inverse predictor of coronary atherosclerotic disease. Preliminary data have suggested that HDL infusions can induce atherosclerosis regression.

Objective  To investigate the effects of reconstituted HDL on plaque burden as assessed by intravascular ultrasound (IVUS).

Design and Setting  A randomized placebo-controlled trial was conducted at 17 centers in Canada. Intravascular ultrasound was performed to assess coronary atheroma at baseline and 2 to 3 weeks after the last study infusion.

Patients  Between July 2005 and October 2006, 183 patients had a baseline IVUS examination and of those, 145 had evaluable serial IVUS examinations after 6 weeks.

Intervention  Sixty patients were randomly assigned to receive 4 weekly infusions of placebo (saline), 111 to receive 40 mg/kg of reconstituted HDL (CSL-111); and 12 to receive 80 mg/kg of CSL-111.

Main Outcome Measures  The primary efficacy parameter was the percentage change in atheroma volume. Nominal changes in plaque volume and plaque characterization index on IVUS and coronary score on quantitative coronary angiography were also prespecified end points.

Results  The higher-dosage CSL-111 treatment group was discontinued early because of liver function test abnormalities. The percentage change in atheroma volume was –3.4% with CSL-111 and –1.6% for placebo (P = .48 between groups, P<.001 vs baseline for CSL-111). The nominal change in plaque volume was –5.3 mm³ with CSL-111 and –2.3 mm³ with placebo (P = .39 between groups, P<.001 vs baseline for CSL-111). The mean changes in plaque characterization index on IVUS (–0.0097 for CSL-111 and 0.0128 with placebo) and mean changes in coronary score (–0.039 mm for CSL-111 and –0.071 mm with placebo) on quantitative coronary angiography were significantly different between groups (P = .01 and P =.03, respectively). Administration of CSL-111 40 mg/kg was associated with mild, self-limiting transaminase elevation but was clinically well tolerated.

Conclusion  Short-term infusions of reconstituted HDL resulted in no significant reductions in percentage change in atheroma volume or nominal change in plaque volume compared with placebo but did result in statistically significant improvement in the plaque characterization index and coronary score on quantitative coronary angiography. Elevation of HDL remains a valid target in vascular disease and further studies of HDL infusions, including trials with clinical end points, appear warranted.

Trial Registration  clinicaltrials.gov Identifier: NCT00225719

Published online: March 26, 2007 (doi:10.1001/jama.297.15.jpc70004).

Author Affiliations: Montreal Heart Institute and the Montreal Heart Institute Coordinating Center (MHICC), Université de Montréal, Montreal, Quebec (Drs Tardif, Grégoire, L’Allier, Ibrahim, Lespérance, Heinonen, Berry, Lavoie, and Guertin); Centre Hospitalier Regional de Lanaudiere, Joliette, Quebec (Dr Kouz); CSL Ltd, Parkville, Australia (Dr Basser); and Quebec Heart Institute–Laval Hospital, Quebec City, Quebec (Dr Rodés-Cabau).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

HDL as a Biomarker, Potential Therapeutic Target, and Therapy
Navab et al.
Diabetes 2009;58:2711-2717.
FULL TEXT  

Extended-Release Niacin or Ezetimibe and Carotid Intima-Media Thickness
Taylor et al.
NEJM 2009;361:2113-2122.
ABSTRACT | FULL TEXT  

Reconstituted High-Density Lipoprotein Attenuates Platelet Function in Individuals With Type 2 Diabetes Mellitus by Promoting Cholesterol Efflux
Calkin et al.
Circulation 2009;120:2095-2104.
ABSTRACT | FULL TEXT  

A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids
Navab et al.
J. Lipid Res. 2009;50:1538-1547.
ABSTRACT | FULL TEXT  

High high-density lipoprotein-cholesterol reduces risk and extent of percutaneous coronary intervention-related myocardial infarction and improves long-term outcome in patients undergoing elective percutaneous coronary intervention
Sattler et al.
Eur Heart J 2009;30:1894-1902.
ABSTRACT | FULL TEXT  

Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection
Sattler and Levkau
Cardiovasc Res 2009;82:201-211.
ABSTRACT | FULL TEXT  

High-Density Lipoprotein Modulates Glucose Metabolism in Patients With Type 2 Diabetes Mellitus
Drew et al.
Circulation 2009;119:2103-2111.
ABSTRACT | FULL TEXT  

Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes.
Patel et al.
J Am Coll Cardiol 2009;53:962-971.
ABSTRACT | FULL TEXT  

Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis
Briel et al.
BMJ 2009;338:b92-b92.
ABSTRACT | FULL TEXT  

High-density lipoprotein: why all the fuss?
Mackness and Mackness
Ann Clin Biochem 2009;46:5-7.
ABSTRACT | FULL TEXT  

Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis: Insights From ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation)
Nicholls et al.
Circulation 2008;118:2506-2514.
ABSTRACT | FULL TEXT  

Effect of Leucine to Phenylalanine Substitution on the Nonpolar Face of a Class A Amphipathic Helical Peptide on Its Interaction with Lipid: HIGH RESOLUTION SOLUTION NMR STUDIES OF 4F-DIMYRISTOYLPHOSPHATIDYLCHOLINE DISCOIDAL COMPLEX
Mishra et al.
J. Biol. Chem. 2008;283:34393-34402.
ABSTRACT | FULL TEXT  

Infusion of Reconstituted High-Density Lipoprotein Leads to Acute Changes in Human Atherosclerotic Plaque
Shaw et al.
Circ. Res. 2008;103:1084-1091.
ABSTRACT | FULL TEXT  

Necrotic core thickness and positive arterial remodeling index: emergent biomechanical factors for evaluating the risk of plaque rupture
Ohayon et al.
Am. J. Physiol. Heart Circ. Physiol. 2008;295:H717-H727.
ABSTRACT | FULL TEXT  

Rimonabant and Progression of Atherosclerosis in Obese Persons--Reply
Nissen et al.
JAMA 2008;300:280-281.
FULL TEXT  

Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-I Milano/1-palmitoyl-2-oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques: in vivo assessment by intravascular ultrasound and magnetic resonance imaging.
Parolini et al.
J Am Coll Cardiol 2008;51:1098-1103.
ABSTRACT | FULL TEXT  

Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis.
Ibanez et al.
J Am Coll Cardiol 2008;51:1104-1109.
ABSTRACT | FULL TEXT  

The year in atherothrombosis.
Sanz et al.
J Am Coll Cardiol 2008;51:944-955.
FULL TEXT  

Anti-Inflammatory and Cardioprotective Activities of Synthetic High-Density Lipoprotein Containing Apolipoprotein A-I Mimetic Peptides
Gomaraschi et al.
J. Pharmacol. Exp. Ther. 2008;324:776-783.
ABSTRACT | FULL TEXT  

High-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh et al.
JAMA 2007;298:786-798.
ABSTRACT | FULL TEXT